Latest Incyte News & Updates

See the latest news and media coverage for Incyte. We track all announcements, press releases, and industry mentions in real time, all in one place.

Incyte

Global biopharmaceutical company

incyte.com

Headquarters: Wilmington, United States
Company type: Public company
Number of employees: 3,000–5,000

Last updated Today

Latest news about Incyte

In short: Incyte reported strong 2026 financial growth, secured FDA approval for Jakafi XR, and advanced its pipeline through several key drug acquisitions.

Company announcements

June 19 Incyte

Incyte Japan announces approval of Minjuvi for DLBCL

The combination with lenalidomide was approved by Japan's MHLW for relapsed or refractory diffuse large B-cell lymphoma.

June 14 Incyte

Incyte announces positive Phase 2 results for zilurgisertib in FOP

The PROGRESS study showed reduced heterotopic ossification and FDA accepted NDA under Priority Review.

June 13 Incyte

Incyte's tafasitamab combination prolonged progression-free survival in DLBCL

The Tafa-Len-R-CHOP regimen reduced risk of disease progression or death by 25% compared to R-CHOP. Data presented at EHA 2026 Congress.

June 13 Incyte

Incyte announces positive EHA 2026 data for INCA033989

The drug achieved rapid, robust clinical and molecular responses and was well tolerated in MF and ET patients.

Media coverage

Yesterday The Globe and Mail

Incyte Resolves Opzelura Medicaid Dispute, Gains One-Time Benefit

Incyte ( (INCY)) has issued an update. Incyte Corporation has reached an agreement with the Centers for Medicare & Medicaid Services to resolve litigation over...

June 20 MyChesCo

Incyte Trial Data Support New First-Line Approach in Lymphoma - MyChesCo

WILMINGTON, DE — Incyte (Nasdaq: INCY) reported Phase III trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk...

June 19 AFP

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell ...

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi ® (tafasitamab) in combination with lenalidomide for...

June 16 AD HOC NEWS

Incyte Stock (US45337C1027): Clinical data and earnings outlook keep Nasdaq biotech in focus

Incyte shares stay in focus on Nasdaq as investors weigh fresh clinical trial results, a recent S&P 500 swing and updated long-term revenue projections while...

Never miss news about Incyte

Track Incyte and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Incyte competitors & trending companies

Browse news for competitors to Incyte and other trending companies.